Fespixon is included in the 2024 TSOC/TSPS Joint Consensus and has been published by a renowned SCI journal, Acta Cardiologica Sinica.

Published Date:2024-01-29

Original Link:https://www.onenessbio.com/en/news_detail262_5.htm

Statement
No	1	Date of announcement	2024/01/29	Time of announcement	22:06:46
Subject	Fespixon is included in the 2024 TSOC/TSPS Joint Consensus and has been published by a renowned SCI journal, Acta Cardiologica Sinica.
To which item it meets	paragraph 53			Date of events	2024/01/29
Date of occurrence of the event: 2024/01/29 Company name: ONENESS BIOTECH CO., LTD. Relationship to the Company (please enter ”head office” or ”subsidiaries”): head office Reciprocal shareholding ratios: NA Cause of occurrence: The Taiwan Society of Cardiology (TSOC) and Taiwan Society of Plastic Surgery (TSPS) have established a consensus of “Strategies for Advanced Vascular Wound Management in Arterial and Venous Diseases”. The use of Fespixon has been included in the consensus as below description:“Topical agents are essential for wound care. A recent novel macrophage-regulating drug, ON101 cream (Fespixon), showed a promising effect on wound healing in patients with diabetic foot ulcers. It may be administered as additional therapy for diabetes patients with ischemic ulcers after debridement and revascularization”. Countermeasures: None Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): This consensus will strengthen the confidence of physicians in the treatment of ischemic diabetic foot ulcers and benefit more patients.